Literature DB >> 29484345

Hospitalization Drug Regimen Changes in Geriatric Patients and Adherence to Modifications by General Practitioners in Primary Care.

L Rouch1, F Farbos, C Cool, C McCambridge, C Hein, S Elmalem, Y Rolland, B Vellas, P Cestac.   

Abstract

OBJECTIVES: To evaluate the overall rate of adherence by general practitioners (GPs) to treatment modifications suggested at discharge from hospital and to assess the way communication between secondary and primary care could be improved.
DESIGN: Observational prospective cohort study.
SETTING: Patients hospitalized from the emergency department to the acute geriatric care unit of a university hospital. PARTICIPANTS: 206 subjects with a mean age of 85 years. MEASUREMENTS: Changes in drug regimen undertaken during hospitalization were collected with the associated justifications. Adherence at one month by GPs to treatment modifications was assessed as well as modifications implemented in primary care with their rationale in case of non-adherence. Community pharmacists' and GPs' opinions about quality of communication and information transfer at hospital-general practice interface were investigated.
RESULTS: 5.5 ± 2.8 drug regimen changes were done per patient during hospitalization. The rate of adherence by GPs to treatment modifications suggested at discharge from hospital was 83%. In most cases, non-adherence by GPs to treatment modifications done during hospitalization was due to dosage adjustments, symptoms resolution but also worsening of symptoms. The last of which was particularly true for psychotropic drugs. All GPs received their patients' discharge letters but the timely dissemination still needs to be improved. Only 6.6% of community pharmacists were informed of treatment modifications done during their patients' hospitalization.
CONCLUSION: Our findings showed a successful rate of adherence by GPs to treatment modifications suggested at discharge from hospital, due to the fact that optimization was done in a collaborative way between geriatricians and hospital pharmacists and that justifications for drug regimen changes were systematically provided in discharge letters. Communication processes at the interface between secondary and primary care, particularly with community pharmacists, must be strengthened to improve seamless care.

Entities:  

Keywords:  Potentially inappropriate prescribing; adherence by general practitioners; communication; hospitalization treatment modifications; primary-secondary care interface

Mesh:

Year:  2018        PMID: 29484345     DOI: 10.1007/s12603-017-0940-1

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  26 in total

1.  Posthospital medication discrepancies: prevalence and contributing factors.

Authors:  Eric A Coleman; Jodi D Smith; Devbani Raha; Sung-joon Min
Journal:  Arch Intern Med       Date:  2005-09-12

Review 2.  Polypharmacy and the geriatric patient.

Authors:  Bryan D Hayes; Wendy Klein-Schwartz; Fermin Barrueto
Journal:  Clin Geriatr Med       Date:  2007-05       Impact factor: 3.076

3.  Do general practitioners and community pharmacists want information on the reasons for drug therapy changes implemented by secondary care?

Authors:  A Munday; B Kelly; J W Forrester; A Timoney; E McGovern
Journal:  Br J Gen Pract       Date:  1997-09       Impact factor: 5.386

Review 4.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

5.  Unintended medication discrepancies at the time of hospital admission.

Authors:  Patricia L Cornish; Sandra R Knowles; Romina Marchesano; Vincent Tam; Steven Shadowitz; David N Juurlink; Edward E Etchells
Journal:  Arch Intern Med       Date:  2005-02-28

6.  The benefits of a hospital based community services liaison pharmacist.

Authors:  K Brookes; M G Scott; J B McConnell
Journal:  Pharm World Sci       Date:  2000-04

7.  Clinical medication review by a pharmacist of elderly people living in care homes--randomised controlled trial.

Authors:  Arnold Geoffrey Zermansky; David Phillip Alldred; Duncan Robert Petty; David K Raynor; Nick Freemantle; Joanne Eastaugh; Peter Bowie
Journal:  Age Ageing       Date:  2006-08-12       Impact factor: 10.668

8.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.

Authors:  P Gallagher; C Ryan; S Byrne; J Kennedy; D O'Mahony
Journal:  Int J Clin Pharmacol Ther       Date:  2008-02       Impact factor: 1.366

9.  The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries.

Authors:  Anna Renom-Guiteras; Gabriele Meyer; Petra A Thürmann
Journal:  Eur J Clin Pharmacol       Date:  2015-05-14       Impact factor: 2.953

10.  The influence of hospitalisation on drug prescription in primary care--a large-scale follow-up study.

Authors:  Thomas Grimmsmann; Ulrike Schwabe; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2007-06-05       Impact factor: 3.064

View more
  3 in total

1.  Letter to the editor: Hospitalization Drug Regimen Changes in Geriatric Patients and Adherence to Modifications by General Practioners in Primary Care.

Authors:  M Wilcock; L Kelly; A Hill
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

2.  Impact of emergency hospital admissions on patterns of primary care prescribing: a retrospective cohort analysis of electronic records in England.

Authors:  Rachel Denholm; Richard Morris; Sarah Purdy; Rupert Payne
Journal:  Br J Gen Pract       Date:  2020-05-28       Impact factor: 5.386

3.  An Innovative Day Hospital Dedicated to Nursing Home Resident: A Descriptive Study of 1306 Residents Referred by their Physicians.

Authors:  C Laffon de Mazières; M Romain; S Hermabessière; G Abellan; S Gerard; A Castex; T Krams; B Vellas; Y Rolland
Journal:  J Nutr Health Aging       Date:  2018       Impact factor: 4.075

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.